Emerging targeted therapies and strategies to overcome resistance in biliary tract cancers
-
Published:2024-07
Issue:
Volume:199
Page:104388
-
ISSN:1040-8428
-
Container-title:Critical Reviews in Oncology/Hematology
-
language:en
-
Short-container-title:Critical Reviews in Oncology/Hematology
Author:
Demir TarikORCID,
Moloney Carolyn,
Mahalingam Devalingam
Reference174 articles.
1. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study;Abou-Alfa;Lancet Oncol.,2020
2. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study;Abou-Alfa;Lancet Oncol.,2020
3. RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives;Addeo;Pharm. Ther.,2023
4. Genetic profiling of intrahepatic cholangiocarcinoma;Andersen;Curr. Opin. Gastroenterol.,2012
5. Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient solid tumors: a nonrandomized controlled trial;André;JAMA Netw. Open,2023